References

1. Schnippel K, Rosen S, Shearer K, Martinson N, Long L, Sanne I et al. Scaling up Xpert MTB/RIF technology: the costs of laboratory- vs; “clinic-based roll-out in South Africa”. Tropical Medicine and International Health. 2012; (9): 1142-1151. PubMed | Google Scholar


2. World Health Organization. Rapid implementation of the Xpert MTB/RIF diagnostic test, Technical and operational ‘How-to’. “Practical considerations”, World Health Organization, Geneva, Switzerland, 2011. Google Scholar


3. Vassall A, Kampen SV, Sohn H, Michael JS, Boon S, Davis JS et al. Rapid diagnosis of tuberculosis with the Xpert MTB/RIF assay in high burden countries: a cost- effectiveness analysis. PLoS Medicine. 2011; 8 (11): e1001120. PubMed | Google Scholar


4. Sohn H, Minion J, Albert H, Dheda K, Pai M. TB diagnostic tests: how do we figure out their costs? Expert Review of Anti Infective Therapy. 2009; 7(6): 723-733. PubMed | Google Scholar


5. World Health Organization. Global Tuberculosis Report, Geneva. Elsevier, 2009. Google Scholar


6. Federal Ministry of Health, Nigeria. National Tuberculosis and Leprosy Control Programme, Annual Report. 2009. Google Scholar


7. Shan M, Chihota V, Coetzee G, Churchyard G, Dorman SE. Comparison of laboratory costs of rapid molecular tests and conventional diagnostics for detection of tuberculosis and drug-resistant tuberculosis in South Africa. Bio Med Central Infectious Diseases. 2013; 13: 352. PubMed | Google Scholar


8. Schnippel K, Meyer-Rath G, Long L, Stevens SW, Sanne I et al. Diagnosing Xpert MTB /RIF-negative TB : Impact and cost of alternative algorithms for South Africa. South African Medical Journal. 2013; 103(2):101-106. PubMed | Google Scholar